GLOBAL VIRAL VECTOR VACCINES MANUFACTURING MARKET FORECAST 2019-2027

  • You are here:
  • Home
  • Reports
  • GLOBAL VIRAL VECTOR VACCINES MANUFACTURING MARKET FORECAST 2019-2027

GLOBAL VIRAL VECTOR VACCINES MANUFACTURING MARKET FORECAST 2019-2027

The Global DNA Sequencing market is anticipated to grow from $ 7898 million in 2017 to $34087 million by 2026, at a CAGR of 17.64% between 2018 and 2026. DNA sequencing is the determination of the order of four chemical buildings blocks called as “the bases” that are responsible for the formation of DNA molecule. The DNA Sequencing market is primarily driven by the following factors:

GLOBAL VIRAL VECTOR VACCINES MANUFACTURING MARKET FORECAST 2019-2027

Request free sample

The global viral vector vaccine manufacturing market is anticipated to grow at a CAGR of 18.19% between 2019 and 2027. Viral vector vaccines are a radical new approach in vaccination that uses live viruses to carry DNA into human cells. The Viral vector vaccine manufacturing market is primarily driven by the following factors:

  • Promising results from several clinical studies
  • The mounting number of viral vectors gene-therapy-based clinical trials
  • Growing chronic diseases

The important drivers increasing growth in the global viral vector vaccine manufacturing market are promising results from several clinical studies and growing chronic diseases. Viral-vector-based clinical trials initiated a surge of investments in drug development and commercialization. Several clinical trials for viral-vector based medicine are being carried out by various institutes and other research centres to check its utility in medication for treatment. The growing prevalence of chronic diseases is leading to increased demand for viral vector vaccines. The most prevalent chronic diseases are cancer, cardiovascular disease, tuberculosis, HIV and others.

The types of viral vector vaccine manufacturing market are used extensively for various purposes. Adenoviral vector has become a majorly exploited vector for advanced vaccine development. The advancements in the retroviral vector are expected to boost the global viral vector vaccine manufacturing market’s retroviral vector segment. Retrovirals have several key characteristics compared to conventional modes of gene delivery such as microinjection, electroporation, and transfection. Lent viral vector is also a type of retroviral vector that can infect both non-dividing and dividing cells since the pre-integration complex formed, which is also referred to as virus shell and can simply penetrate the integral membrane of the nucleus of a targeted cell. There are several ongoing clinical trials with AAV vector for development of a vaccine to treat eye and muscle diseases. Poxvirus is the most commonly known DNA virus and is distinguished from other viruses through its capability to reproduce completely in the cytoplasm available across the host cell and present external to the nucleus. Cytomegalovirus has extensive application in the development of notably precise and cost-effective vaccines for the treatment of diseases such as HIV/AIDS and cancer.

Poor reimbursement system and stringent government policies are the major factors hindering the viral vector vaccine manufacturing market. The poor reimbursement system is a major restraint which restricts the individuals to go for cancer detection tests and affects viral vaccines market constituting cancer in a negative way. Government policies must be favourable for research and development to help in the growth of the market.

The Global Viral vector vaccine manufacturing market segments include types, diseases, and applications.

Types are segmented into:

  • Adenoviral vectors
  • Retroviral vectors
  • Lent viral vectors
  • Adeno-associated viral vectors
  • Poxvirus
  • Cytomegalovirus
  • Other viral vectors

Diseases are segmented into:

  • Human diseases
    • Hepatitis
    • Cancer
    • Malaria
    • Tuberculosis
    • Influenza
    • HIV
    • Other human diseases
  • Veterinary diseases
    • Avian influenza
    • Marek’s disease
    • Infectious bronchitis
    • PPR disease
    • Other veterinary diseases

Applications are segmented into:

  • Multivalent
  • Multi-pathogen

This report covers the present market conditions and the growth prospects of the global viral vector vaccine manufacturing market for 2019-2027 and considered the revenue generated through the sales of Viral vector vaccine manufacturing by types, diseases, and applications to calculate the market size by considering 2018 as the base year.

Geographically, the global viral vector vaccine manufacturing market has been segmented on the basis of four major regions, which include:

  • North America: The United States & Canada
  • Asia-Pacific: China, India, Japan, Australia, South Korea & Rest of APAC
  • Europe: The United Kingdom, France, Germany, Spain, Italy & Rest of Europe
  • Rest of World: Latin America and the Middle East and Africa

The Viral vector vaccine manufacturing market in Europe is expected to hold the largest share by 2027 on account of the growing R&D expenditure for viral vectors, and the growing number of livestock diseases in Europe. A rise in the HPAI outbreaks in domestic birds in the region is also fueling the adoption of viral-vector-based vaccines, thereby driving the market for viral vector vaccine manufacturing. On the other hand, the North America market is anticipated to be the fastest-growing region for the global viral vector vaccine manufacturing market. The North America viral vector vaccine manufacturing market is primarily driven by the rising clinical trials in viral vectors and increasing government funding in cancer research. Moreover, the high prevalence of genetic disorders and chronic diseases and government investment in gene-editing tools and research funding for gene research are also fueling the market growth.

The viral vector vaccine manufacturing market is segmented on the basis of diseases which are sub-divided into human diseases and veterinary diseases.  The application segment of the market is sub-divided into multivalent and multi-pathogen. The multivalent viral vectors possess the property of having various antigens that prove beneficial for prevention against diseases. The multi-pathogen viral vector vaccines present antigen in a unique way and are capable of expressing various transgenes at once. Viral vector vaccines have potential application in the prevention and protection of humans from diseases such as influenza, cancer, and tuberculosis. Viral vector systems that have been premeditated in vaccinology are adeno-associated virus vectors and poxvirus vectors. Viral-vectored vaccines, specifically using vectors such as pox virus, herpes virus, and adenovirus are increasingly being used in veterinary medicine, where viral vector technology has been adopted more rapidly than in human medicine.

The major market players of the global viral vector vaccine manufacturing market are:

  • Biogen Idec (Now Biogen Inc.)
  • Advanced Bioscience Laboratories Inc.
  • Batavia Biosciences
  • Cobra Biologics (Subsidiary Of Recip Ab)
  • GE Healthcare

Company Profiles covers analysis of important players.

Biogen Inc. (or ‘the company’), formerly known as Biogen Idec, a biopharmaceutical company, focuses on the development, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. GE Healthcare (or ‘the company’) is a medical technology business unit of General Electric (GE). The unit is a global provider of medical technologies and services for the diagnosis and treatment of cancer, heart disease, neurological diseases, women’s health, and other conditions.

Key Findings of the Global Viral vector vaccine manufacturing market:

  • Poxvirus constitutes the largest market share in terms of types
  • Human diseases are anticipated to grow significantly during the forecast period
  • Multivalent applications are widely used in the viral vector manufacturing market
  1. RESEARCH SCOPE
    • STUDY GOALS
    • SCOPE OF THE MARKET STUDY
    • WHO WILL FIND THIS REPORT USEFUL?
    • STUDY AND FORECASTING YEARS
  2. RESEARCH METHODOLOGY
    • SOURCES OF DATA
      • SECONDARY DATA
      • PRIMARY DATA
    • TOP DOWN APPROACH
    • BOTTOM-UP APPROACH
    • DATA TRIANGULATION
  3. EXECUTIVE SUMMARY
    • MARKET SUMMARY
    • KEY FINDINGS
      • POX VIRUS CONSTITUTES THE LARGEST MARKET SHARE IN TERMS OF TYPES
      • HUMAN DISEASES ARE ANTICIPATED TO GROW SIGNIFICANTLY DURING THE FORECAST PERIOD
      • MULTIVALENT APPLICATIONS ARE WIDELY USED IN THE VIRAL VECTOR MANUFACTURING MARKET
  1. MARKET DETERMINANTS
    • MARKET DRIVERS
      • PROMISING RESULTS FROM SEVERAL CLINICAL STUDIES
      • MOUNTING NUMBER OF VIRAL VECTORS GENE-THERAPY-BASED CLINICAL TRIALS
      • GROWING CHRONIC DISEASES
    • MARKET OPPORTUNITIES
      • SWELLING INVESTMENT IN GENE-THERAPY-BASED R&D ACTIVITIES
      • INCREASE IN THE RESEARCH AND DEVELOPMENT
    • MARKET RESTRAINTS
      • POOR REIMBURSEMENT SYSTEM
      • STRINGENT GOVERNMENT POLICIES
    • MARKET CHALLENGES
      • UNFAVOURABLE COMPENSATION SITUATION
      • PRICING PRESSURE COUPLED WITH LACK OF PRODUCT DIFFERENTIATION
      • RIGOROUS REGULATORY AGENDA
  1. MARKET SEGMENTATION
    • MARKET BY TYPES 2019-2027
      • ADENOVIRAL VECTORS
      • RETROVIRAL VECTORS
      • LENTIVIRAL VECTORS
      • ADENO-ASSOCIATED VIRAL VECTORS
      • POXVIRUS
      • CYTOMEGALOVIRUS
      • OTHER VIRAL VECTORS
    • MARKET BY APPLICATION 2019-2027
      • MULTIVALENT
      • MULTIPATHOGEN
    • MARKET BY DISEASES 2019-2027
      • HUMAN DISEASES
        • HEPATITIS
        • CANCER
        • MALARIA
        • TUBERCULOSIS
        • INFLUENZA
        • HIV
        • OTHER HUMAN DISEASES
      • VETERINARY DISEASES
        • AVIAN INFLUENZA
        • MAREK’S DISEASE
        • INFECTIOUS BRONCHITIS
        • PPR DISEASE
        • OTHER VETERINARY DISEASES
  1. KEY ANALYTICS
    • EVOLUTION AND TRANSITION
    • REGULATORY FRAMEWORK
      • THE UNITED STATES
      • EUROPEAN UNION
      • ASIA PACIFIC
        • AUSTRALIA
        • JAPAN
        • INDIA
        • CHINA
      • KEY PROPERTIES OF VIRAL VECTOR
      • CHARACTERISTICS OF POTENTIAL VIRAL VACCINE VECTORS
      • PATENT ANALYSIS
        • THE UNITED STATES PATENT ANALYSIS
        • EUROPE PATENT ANALYSIS
        • JAPAN PATENT ANALYSIS
      • MANUFACTURING PROCESS OF A VIRAL-VECTOR
      • SMALL-SCALE MANUFACTURING PROCESS OF ADENOVIRUS
      • KEY SUPPLIERS IN VIRAL VECTOR MARKET
      • KEY BUYING CRITERIA
  1. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • THE UNITED STATES
      • CANADA
    • EUROPE
      • GERMANY
      • THE UNITED KINGDOM
      • FRANCE
      • SPAIN
      • ITALY
      • REST OF THE EUROPE
    • ASIA-PACIFIC
      • CHINA
      • INDIA
      • JAPAN
      • AUSTRALIA
      • SOUTH KOREA
      • REST OF ASIA-PACIFIC
    • REST OF THE WORLD
      • LATIN AMERICA
      • MIDDLE EAST AND AFRICA
  1. COMPANY PROFILES
    • ADVANCED BIOTHERAPEUTICS CONSULTING
    • ADVANCED BIOSCIENCE LABORATORIES INC.
    • APPLIED VIROMICS
    • BATAVIA BIOSCIENCES
    • BENITEC BIOPHARMA
    • BIOGEN IDEC (NOW BIOGEN INC.)
    • BIOVIAN
    • BRAMMER BIO
    • BOEHRINGER INGELHEIM GMBH
    • CELL AND GENE THERAPY CATAPULT
    • CEVA CORPORATE
    • COBRA BIOLOGICS (SUBSIDIARY OF RECIP AB)
    • GE HEALTHCARE
    • JANSSEN PHARMACEUTICAL INC.
    • ID PHARMA CO. LTD.

 

LIST OF TABLES

TABLE  1      GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET BY GEOGRAPHY 2019-2027 ($ THOUSAND)

TABLE  2      ONGOING CLINICAL TRIALS RELATED TO VIRAL VECTORS

TABLE  3      VARIOUS VIRAL VECTORS PROPERTIES AND THEIR APPLICATION IN GENE THERAPY

TABLE  4      GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET BY TYPES 2019-2027 ($ THOUSANDS)

TABLE  5      KEY VIRAL VECTORS CHARACTERISTICS

TABLE  6      GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET IN ADENOVIRAL VECTORS BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE  7      GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET IN RETROVIRAL VECTORS BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE  8      ADVANTAGES AND DISADVANTAGES OF RETROVIRAL VECTORS

TABLE  9      COMPONENTS OF HIV PROVIRUS

TABLE  10    GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET IN LENTIVIRAL VECTORS BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE  11    SECOND- VS. THIRD-GENERATION LENTIVIRAL SYSTEMS

TABLE  12    AAV VECTORS WITH THEIR TROPISMS AND RECEPTORS

TABLE  13    GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET IN ADENO-ASSOCIATED VIRAL VECTORS BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE  14    LICENSED FOWL POX VIRAL-VECTORED VETERINARY VACCINES

TABLE  15    GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET IN POX VIRUS BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE  16    GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET IN CYTOMEGALOVIRUS BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE  17    GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET IN OTHER VIRAL VECTORS BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE  18    GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET BY APPLICATION 2019-2027 ($ THOUSANDS)

TABLE  19    GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET IN MULTIVALENT BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE  20    REGION WISE TB STATISTICS FOR 2016

TABLE  21    GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET IN MULTIPATHOGEN BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE  22    GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET BY DISEASES 2019-2027 ($ THOUSANDS)

TABLE  23    GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET IN HUMAN DISEASES BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE  24    GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET IN HUMAN DISEASES BY TYPES 2019-2027 ($ THOUSANDS)

TABLE  25    GLOBAL HUMAN DISEASES  MARKET IN HEPATITIS BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE  26    ESTIMATED ACTUAL NEW CASES OF HAV

TABLE  27    GLOBAL HUMAN DISEASES  MARKET IN CANCER BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE  28    ESTIMATED NEW CANCER CASES IN THE UNITED STATES 2017

TABLE  29    GLOBAL HUMAN DISEASES  MARKET IN MALARIA BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE  30    MALARIA VACCINE DEVELOPMENT INITIATIVES

TABLE  31    VIRAL VECTOR VACCINE CANDIDATES FOR TUBERCULOSIS

TABLE  32    GLOBAL HUMAN DISEASES  MARKET IN TUBERCULOSIS BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE  33    GLOBAL HUMAN DISEASES  MARKET IN INFLUENZA BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE  34    BENEFITS AND CONCERN FOR VIRUS-VECTORED EXPERIMENTAL INFLUENZA VACCINES

TABLE  35    GLOBAL HUMAN DISEASES  MARKET IN HIV BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE  36    GLOBAL HUMAN DISEASES  MARKET IN OTHER HUMAN DISEASES BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE  37    ONGOING CLINICAL TRIALS AND DEVELOPMENT IN ZIKA VIRUS VACCINE

TABLE  38    LICENSED VIRAL-VECTORED VETERINARY VACCINES

TABLE  39    GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET IN VETERINARY DISEASES BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE  40    GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET IN VETERINARY DISEASES BY TYPES  2019-2027 ($ THOUSANDS)

TABLE  41    AVIAN INFLUENZA VACCINES

TABLE  42    GLOBAL VETERINARY DISEASES MARKET IN AVIAN INFLUENZA BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE  43    GLOBAL VETERINARY DISEASES MARKET IN MAREK’S DISEASE BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE  44    MAREK’S DISEASE VACCINES

TABLE  45    GLOBAL VETERINARY DISEASES MARKET IN INFECTIOUS BRONCHITIS BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE  46    GLOBAL VETERINARY DISEASES MARKET IN PPR DISEASE BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE  47    GLOBAL VETERINARY DISEASES MARKET IN OTHER VETERINARY DISEASES BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE  48    GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET BY GEOGRAPHY 2019-2027 ($ THOUSANDS)

TABLE  49    NORTH AMERICA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

TABLE  50    FUNDING IN CANCER RESEARCH IN THE UNITED STATES ($ MILLIONS)

TABLE  51    THE UNITED STATES  VIRAL VECTOR VACCINE MANUFACTURING MARKET BY TYPES 2019-2027 ($ THOUSANDS)

TABLE  52    NIH FUNDING FOR CRISPR-RELATED RESEARCH 2006-2016 ($)

TABLE  53    CANADA VIRAL VECTOR VACCINE MANUFACTURING MARKET BY TYPES 2019-2027 ($ THOUSANDS)

TABLE  54    EUROPE VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

TABLE  55    GERMANY VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 BY TYPES ($ THOUSANDS)

TABLE  56    THE UNITED KINGDOM VIRAL VECTOR VACCINE MANUFACTURING MARKET BY TYPES 2019-2027 ($ THOUSANDS)

TABLE  57    FRANCE VIRAL VECTOR VACCINE MANUFACTURING MARKET BY TYPES 2019-2027 ($ THOUSANDS)

TABLE  58    SPAIN VIRAL VECTOR VACCINE MANUFACTURING MARKET BY TYPES  2019-2027 ($ THOUSANDS)

TABLE  59    ITALY VIRAL VECTOR VACCINE MANUFACTURING MARKET BY TYPES 2019-2027 ($ THOUSANDS)

TABLE  60    ASIA-PACIFIC  VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

TABLE  61    CHINA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 BY TYPES ($ THOUSANDS)

TABLE  62    ONGOING PRECLINICAL AND CLINICAL TRIALS OF HIV/AIDS VACCINE IN CHINA

TABLE  63    PREVALENCE OF TUBERCULOSIS IN INDIA 2016

TABLE  64    INDIAVIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 BY TYPES ($ THOUSANDS)

TABLE  65    CLINICAL TRIALS RELATED TO HIV VACCINE IN INDIA

TABLE  66    JAPAN VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 BY TYPES ($ THOUSANDS)

TABLE  67    AUSTRALIA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 BY TYPES ($ THOUSANDS)

TABLE  68    SOUTH KOREA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 BY TYPES ($ THOUSANDS)

TABLE  69    PRINCIPAL CAUSES OF DEATHS IN SINGAPORE, 2014–2016

TABLE  70    NUMBER OF HIV AND AIDS PEOPLE IN THAILAND 2016

TABLE  71    REST OF WORLD VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

TABLE  72    LATIN AMERICA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 BY TYPES ($ THOUSANDS)

TABLE  73    CAUSES OF DEATH IN CUBA AND PERCENTAGE CHANGE FROM 2005-2016

TABLE  74    MIDDLE EAST AND AFRICA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 BY TYPES ($ THOUSANDS)

TABLE  75    CHARACTERISTICS OF THE PRIORITY DISEASES IDENTIFIED BY THE WHO R&D BLUEPRINT IN MEA 2017

 

LIST OF FIGURES

FIGURE  1    GLOBAL VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSAND)

FIGURE  2    SCHEMATIC OVERVIEW OF MULTIVALENT AND MULTIPATHOGEN VIRAL VECTOR VACCINES

FIGURE  3    REGION WISE ESTIMATION OF PEOPLE LIVING WITH HIV 2016 (MILLION)

FIGURE  4    REGION WISE PREVALENCE OF HBV INFECTION IN THE GENERAL POPULATION 2015 (MILLIONS)

FIGURE  5    CONFIRMED, PROBABLE AND SUSPECTED EVD CASES WORLDWIDE

FIGURE  6    POULTRY PRODUCTION ESTIMATES WORLDWIDE (MILLION METRIC TONS)

FIGURE  7    VACCINE ADVANCEMENTS TIMELINE

FIGURE  8    STEPS REQUIREMENT FOR VACCINE APPROVAL

FIGURE  9    VACCINE REVIEW AND REGULATION STEPS UNDER FDA

FIGURE  10  VACCINE REVIEW AND REGULATION STEPS UNDER EMA

FIGURE  11  VACCINE REVIEW AND REGULATION STEPS UNDER MHLW

FIGURE  12  APPROVAL PROCESS OF VACCINE IN INDIA

FIGURE  13  MANUFACTURING PROCESS OF ADENOVIRUS

FIGURE  14  THE UNITED STATES VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

FIGURE  15  CANADA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

FIGURE  16  GERMANY VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

FIGURE  17  THE UNITED KINGDOM VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

FIGURE  18  NUMBER OF PEOPLE LIVING WITH HIV IN FRANCE

FIGURE  19  FRANCE VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

FIGURE  20  LEADING CAUSES OF WOMEN DEATH IN FRANCE (%)

FIGURE  21  LEADING CAUSES OF MEN DEATH IN FRANCE (%)

FIGURE  22  SPAIN VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

FIGURE  23  NUMBER OF PEOPLE IN SPAIN INFECTED WITH HIV

FIGURE  24  ITALY VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

FIGURE  25  REST OF THE EUROPE VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

FIGURE  26  NUMBER OF PEOPLE IN REST OF EUROPE INFECTED WITH HIV (THOUSANDS)

FIGURE  27  CHINA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

FIGURE  28  INDIA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

FIGURE  29  JAPAN VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

FIGURE  30  NUMBER OF HIV CASES IN JAPAN 2012 AND 2016

FIGURE  31  AUSTRALIA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

FIGURE  32  VARIOUS VIRAL VACCINE VECTORS USED IN AIDS VACCINE DEVELOPMENT

FIGURE  33  NUMBER OF DIAGNOSED HIV INFECTIONS IN AUSTRALIA 2012–2016

FIGURE  34  SOUTH KOREA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

FIGURE  35  SHARES OF DEATH IN SOUTH KOREA IN 2016 DEATH RATE (PER 100,000 POPULATIONS)

FIGURE  36  REST OF ASIA-PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

FIGURE  37  DIAGNOSED HIV CASES IN THE PHILIPPINES BY AGE GROUP 2016 (%)

FIGURE  38  LATIN AMERICA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

FIGURE  39  MIDDLE EAST AND AFRICA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

  1. MARKET SEGMENTATION
    • MARKET BY TYPES 2019-2027
      • ADENOVIRAL VECTORS
      • RETROVIRAL VECTORS
      • LENT VIRAL VECTORS
      • ADENO-ASSOCIATED VIRAL VECTORS
      • POXVIRUS
      • CYTOMEGALOVIRUS
      • OTHER VIRAL VECTORS
    • MARKET BY APPLICATION 2019-2027
      • MULTIVALENT
      • MULTIPATHOGEN
    • MARKET BY DISEASES 2019-2027
      • HUMAN DISEASES
        • HEPATITIS
        • CANCER
        • MALARIA
        • TUBERCULOSIS
        • INFLUENZA
        • HIV
        • OTHER HUMAN DISEASES
      • VETERINARY DISEASES
        • AVIAN INFLUENZA
        • MAREK’S DISEASE
        • INFECTIOUS BRONCHITIS
        • PPR DISEASE
        • OTHER VETERINARY DISEASES
  1. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • THE UNITED STATES
      • CANADA
    • EUROPE
      • GERMANY
      • THE UNITED KINGDOM
      • FRANCE
      • SPAIN
      • ITALY
      • REST OF THE EUROPE
    • ASIA-PACIFIC
      • CHINA
      • INDIA
      • JAPAN
      • AUSTRALIA
      • SOUTH KOREA
      • REST OF ASIA-PACIFIC
    • REST OF THE WORLD
      • LATIN AMERICA
      • MIDDLE EAST AND AFRICA

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

Choose License Type

Buy Now